Taxol(®)-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor(®) EL.
暂无分享,去创建一个
A. Egberts | R. Schiffelers | N. Sachini | P. Vader | M. Fens | W. V. van Solinge | J. Rasmussen | R. van Wijk | B. V. van Oirschot | C. Gaillard | Grietje Andringa
[1] R. Schiffelers,et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[2] V. Torchilin,et al. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[3] R. Schiffelers,et al. A role for activated endothelial cells in red blood cell clearance: implications for vasopathology , 2012, Haematologica.
[4] Luigi Biancone,et al. Exosomes/microvesicles as a mechanism of cell-to-cell communication. , 2010, Kidney international.
[5] J. Tissot,et al. Analysis and clinical relevance of microparticles from red blood cells , 2010, Current opinion in hematology.
[6] N. Lion,et al. Stored red blood cells: a changing universe waiting for its map(s). , 2010, Journal of proteomics.
[7] A. Falus,et al. Highlights of a new type of intercellular communication: microvesicle-based information transfer , 2009, Inflammation Research.
[8] S. Sadallah,et al. Erythrocyte‐derived ectosomes have immunosuppressive properties , 2008, Journal of leukocyte biology.
[9] L. Margaritis,et al. RBC‐derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components , 2008, Transfusion.
[10] L. Pusztai,et al. Paclitaxel-induced sickle cell crisis. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[11] E. Lasonder,et al. The proteome of red cell membranes and vesicles during storage in blood bank conditions. , 2008, Transfusion.
[12] A. Guha,et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells , 2008, Nature Cell Biology.
[13] J Ratajczak,et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication , 2006, Leukemia.
[14] F. Lang,et al. Mechanisms and significance of eryptosis. , 2006, Antioxidants & redox signaling.
[15] R. Birge,et al. Phosphatidylserine recognition by phagocytes: a view to a kill. , 2006, Trends in cell biology.
[16] William E. Grizzle,et al. Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1 , 2006, The Journal of Immunology.
[17] F. Lang,et al. Stimulation of Erythrocyte Phosphatidylserine Exposure by Paclitaxel , 2006, Cellular Physiology and Biochemistry.
[18] T. Greenwalt,et al. The how and why of exocytic vesicles , 2006, Transfusion.
[19] Michael Hawkins,et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] José A López,et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. , 2005, Blood.
[21] Sebastian Amigorena,et al. Lactadherin promotes VEGF-dependent neovascularization , 2005, Nature Medicine.
[22] Wim E Hennink,et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[23] Jichun Chen,et al. Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. , 2004, Blood.
[24] Kinam Park,et al. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[25] J. Verweij,et al. Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches , 2003, Clinical pharmacology and therapeutics.
[26] R. Nieuwland,et al. Microparticles in cardiovascular diseases. , 2003, Cardiovascular research.
[27] Keiko Miwa,et al. Identification of a factor that links apoptotic cells to phagocytes , 2002, Nature.
[28] P. Hinterdorfer,et al. Ca(++)-dependent vesicle release from erythrocytes involves stomatin-specific lipid rafts, synexin (annexin VII), and sorcin. , 2002, Blood.
[29] B. Setty,et al. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. , 2002, Blood.
[30] J. Dachary-Prigent,et al. Phosphatidylserine‐related adhesion of human erythrocytes to vascular endothelium , 1999, British journal of haematology.
[31] V. Georgoulias,et al. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. , 1998, American journal of clinical oncology.
[32] F. Boas,et al. Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[33] F M Muggia,et al. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.
[34] J. Verweij,et al. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. , 1998, Analytical biochemistry.
[35] A. Schroit,et al. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. , 1997, Blood.
[36] J. Rasmussen,et al. Characterization of glycoprotein PAS-6/7 from membranes of bovine milk fat globules. , 1996, European journal of biochemistry.
[37] J. Beijnen,et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. , 1996, Cancer research.
[38] A. Schroit,et al. Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cells. , 1994, The Journal of biological chemistry.
[39] V. Nussenzweig,et al. Membrane vesiculation protects erythrocytes from destruction by complement. , 1991, Journal of immunology.
[40] E K Rowinsky,et al. Cardiac disturbances during the administration of taxol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] B. Leyland-Jones,et al. Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] D. Ettinger,et al. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. , 1989, Cancer research.
[43] P. Thomas,et al. The isolation and characterization of 60 nm vesicles ('nanovesicles') produced during ionophore A23187-induced budding of human erythrocytes. , 1980, The Biochemical journal.
[44] J. Eaton,et al. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. , 1980, The New England journal of medicine.
[45] P. Schiff,et al. Promotion of microtubule assembly in vitro by taxol , 1979, Nature.
[46] M. Gelderman,et al. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. , 2006, Transfusion medicine reviews.
[47] J. Whang‐Peng,et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] M. Christian,et al. A reassessment of cardiac toxicity associated with Taxol. , 1993, Journal of the National Cancer Institute. Monographs.